Physician profile
Timothy A Young
NPI 1598836173
$2,546.46
in general payments reported to CMS, 2019-2025
28 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $230 · 2021: $324 · 2022: $412 · 2023: $551 · 2024: $301 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $345.21 | 2019-2024 | Biktarvy |
| Novo Nordisk INC | $331.48 | 2019-2024 | Ozempic, Rybelsus |
| Medtronic USA, INC. | $189.37 | 2019 | |
| Abbvie INC. | $176.25 | 2021-2023 | Vraylar |
| Exact Sciences Corporation | $142.96 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $131.60 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.56 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Orexo US, INC. | $119.69 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $108.57 | 2023-2025 | Edarbi, Edarbyclor |
| Sanofi-Aventis U.S. LLC | $105.58 | 2019-2023 | |
| Lilly USA, LLC | $98.69 | 2023-2025 | Mounjaro |
| Amarin Pharma, INC. | $95.15 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $75.08 | 2022-2023 | Seglentis, Livalo |
| Ascensia Diabetes Care US INC. | $69.50 | 2019 | |
| Dexcom, INC. | $55.46 | 2022-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $47.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.52 | 2022-2025 | Farxiga |
| Galt Pharmaceuticals, LLC | $40.61 | 2023 | Orphengesic Forte |
| Bayer Healthcare Pharmaceuticals INC. | $40.48 | 2023 | |
| Eisai INC. | $33.40 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.03 | 2019 | |
| Kaleo, INC. | $23.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.98 | 2019 | |
| Pfizer INC. | $21.75 | 2022 | |
| Indivior INC. | $20.49 | 2019 | |
| Kyowa Kirin, INC. | $18.99 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $16.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.